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Abstract: 
 
Background and aim Biosimilar medicines are not considered exact replicas of originator biologic medicines. 
As a result, prescribers can be hesitant to introduce such medicines into the clinical setting until evidence 
surfaces confirming their safety and effectiveness. In Ireland, a national biosimilar medicines policy is currently 
in development but the decision to prescribe biosimilar medicines remains at the discretion of the physician. The 
aim of this descriptive review is to tell the story of the evidence used by a large acute Irish teaching hospital to 
introduce biosimilar infliximab CT-P13 for the treatment of inflammatory bowel disease (IBD) in a safe and 
timely manner into routine care.  
 
Setting and methods To explore the evidence supporting the effective introduction of biosimilar infliximab in a 
large acute Irish teaching hospital, a literature review was conducted. Evidence consisted of published studies, 
reviews, reports, position statements, articles, clinical guidelines and recommendations from national bodies, 
regulatory authorities and professional organisations. All evidence was published in English. 
 
Results In September 2014, the accumulated evidence base provided physicians with reassurance to prescribe 
biosimilar infliximab CT-P13 for new patients suffering from IBD in this large acute Irish teaching hospital. In 
September 2016, as the evidence base grew, physicians began to safely and confidently switch patients from the 
originator infliximab product to the biosimilar product.  
 
Conclusion There was a significant time lag between regulatory approval and clinical acceptance given that the 
European Medicines Agency (EMA) had granted market authorisation for biosimilar infliximab CT-P13 three 
years prior to the initiation of this hospital’s switching process. Although conservative in their execution, the 
authors conclude that with the existential concern and uncertainty still surrounding biosimilar medicines, a 
distinct and individualised approach for biosimilar medicine implementation is required. It is hoped that the 
Irish biosimilar medicines policy will improve upon biosimilar medicine clinical acceptance once published. 
 
Introduction: 
In 2014, six of the top 10 blockbuster medicines were monoclonal antibodies [1]. In recent times, small 
molecule chemical entity (SMCE) blockbuster drugs like Viagra® and Lipitor®, have been superseded by 
blockbuster biologics such as Humira® and Enbrel®, demonstrating the newly acquired prominence of 
biological medicines [2,3]. However, these large complex proteins (comprised of or derived from living cells or 
organisms) are more complicated than traditional SMCEs due to their unique manufacturing process [4]. Unlike 
generic drugs of SMCEs, biosimilar medicinal products (biosimilars) which aim to replicate originator biologic 
products, have given rise to concerns related to their pharmaceutical quality, safety (especially immunogenicity) 
and efficacy (particularly in extrapolated indications) [5,6]. This can create confusion around the practice of 
interchangeability which is not as lucid for biosimilars as it is for generic drugs of SMCEs [7]. 
                                                                                                                                                       Substitution, 
switching and interchangeability are terms often used when discussing biosimilars. Pharmacists can substitute 
generic drugs of SMCEs in Ireland and the U.K. on the proviso these medicines are deemed interchangeable [7-
9]. The European Medicines Agency (EMA) defines substitution as “the practice of dispensing one medicine 
instead of another equivalent and interchangeable medicine at pharmacy level without consulting the 
prescriber” whilst interchangeability refers to “the possibility of exchanging one medicine for another medicine 
that is expected to have the same clinical effect” [10]. However, pharmacist substitution of biosimilars is not 
currently permitted in most countries [4,11], although pharmacists practising in Australia can substitute some 
biological medicines [12]. In the majority of cases, it appears that pharmacists are bound by legislative 
constraints at the point of dispensing [13]. As a result, physicians are the key stakeholders to switch patients to 
and from different brands of the same or similar biologic medicines, where switching is defined as “when the 
prescriber decides to exchange one medicine for another medicine with the same therapeutic intent” [10].  
                                                                                                                                                                          There 
is no longer a dearth of evidence when it comes to the science and interchangeability status of biosimilar 
medicines. However, knowing when it is most appropriate and timely to implement these medicines into routine 
clinical practice can be difficult. In a large acute Irish teaching hospital, biosimilar infliximab CT-P13 was 
introduced in place of originator brand infliximab (Remicade®), to treat inflammatory bowel disease (IBD). As 
well as Crohn’s disease (CD) and ulcerative colitis (UC), Remicade® is licensed to treat a range of other 
autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis [14]. 
In the absence of a national Irish biosimilar medicines policy and with perceived uncertainty surrounding 
biosimilar medicines, this descriptive review adds to the literature by illustrating the independent systematic 
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evidence base behind the decision-making process to introduce biosimilar infliximab CT-P13 into secondary 
care treatment of IBD.  
Methods: 
In June 2013, biosimilar infliximab was licenced by the EMA [15]. The agency’s committee for medicinal 
products for human use (CHMP) recommended the granting of marketing authorisations for the first two 
monoclonal antibody biosimilars, Remsima® and Inflectra®, both of which contain the same known active 
substance infliximab CT-P13. The decision to provide marketing authorisation for both these infliximab 
biosimilar medicines was based on the same documentation. Their application dossiers demonstrated parallel 
similarity to the biological medicine Remicade®, which has been authorised in the European Union (EU) since 
1999 [15]. Remsima® and Inflectra® are recommended for authorisation in the same indications as Remicade®.   
                                                                          A few weeks after biosimilar infliximab CT-P13 was licensed, the 
European Crohn’s and Colitis Organisation (ECCO) released a position statement. In it, they articulated that 
post-marketing pharmacovigilance and unequivocal identification of infliximab CT-P13 as a biosimilar was in 
place. However, their overall stance on the issue was that the use of most biosimilars in patients with IBD 
should require testing in this particular patient population with comparison to the appropriate innovator product 
(Remicade®) before approval [16]. The ECCO also considered the benefits of wider access with appropriate use 
of biological therapy in IBD and potential direct cost savings important but its primary concern was that 
rigorous testing was necessary in patients with IBD to ensure that appropriate efficacy and safety standards were 
met. The organisation was of the opinion that final clinical decisions should always be made on an individual 
basis, taking into account both the circumstances of the individual patient and the prescribing physician. The 
ECCO defied the practice of extrapolation for biosimilar infliximab at this time. In addition to stance taken by 
the ECCO, several national physician societies initially questioned the marketing authorisations of biosimilars, 
including the extrapolation to IBD. Retrospectively, it became obvious that there was a lack of understanding of 
the biosimilar development concept [17].                                
                                                                  Contrary to the guidance from the ECCO, the chief pharmacist and 
consultant gastroenterologist of a large acute Irish teaching hospital decided to introduce biosimilar infliximab 
CT-P13 for use in new patients in September 2014. Both parties had been documenting the evidence trail since 
the licencing of this biosimilar in June 2013 and believed there was enough accumulated evidence from various 
sources to support their decision [15,18]. This information was relayed to all prescribing physicians during an 
internal staff meeting where the chief pharmacist and consultant gastroenterologist explained the science behind 
their evidence-based decision. All physicians accepted this decision and agreed to prescribe biosimilar 
infliximab CT-P13 for new patients. Physicians agreed to report any adverse drug reactions (ADRs) to the 
Health Products Regulatory Authority (HPRA) in Ireland and to the EMA. Hospital budget co-ordinators were 
pleased given that the biosimilar product was cheaper than the originator brand. With verbal reassurance to 
patients on the safety and efficacy at the point of prescribing, physicians faced no opposition from new patients.  
                                                                         Although this new prescribing practice could have been deemed 
hasty, the British Society of Gastroenterology (BSG) released a position statement with updated guidance two 
months later justifying the introduction of biosimilar infliximab CT-P13 in the clinical setting. The BSG 
recommended that infliximab should be prescribed by brand name [19]. This prescribing practice contradicts the 
trend for SMCE medicines where prescribing generically is encouraged [7]. This statement also proposed the 
use of a prospective registry of all biological use in IBD patients to capture safety data and side effects. For 
patients already on therapy, it was recommended to avoid switching from the originator product to the 
biosimilar, or vice versa, at least until safety data was made available [19].  
                                                                                                                       During the summer of 2015, the 
National Institute for Health and Care Excellence (NICE) remarked positively on the topic of biosimilar 
prescribing. Their report concluded that the EMA was content that the pharmacokinetics, efficacy, safety and 
immunogenicity profiles of  biosimilars were similar to those of the originator product and concluded that the 
recommendations for infliximab could apply both to the originator product and its biosimilars [20]. In addition, 
the HPRA released a guide to biosimilars for healthcare professionals (HCPs) and patients in December 2015. 
This guide discussed the concept of extrapolation in the context of biosimilars where a clinical study is carried 
out in one of the approved indications of the biological medicine and the efficacy data are then extrapolated to 
all authorised indications [11]. As stated in this guide, extrapolation is not unique to the authorisation of 
biosimilars; a similar approach may also be used to deal with post-authorisation changes for reference biological 
medicines.  
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          In February 2016, both the NICE and the BSG updated their previous guidance on this subject. 
The NICE reinforced that all HCPs should ensure biological medicines, including biosimilar medicines, are 
prescribed by brand name so that products cannot be automatically substituted at the point of dispensing. The 
choice of whether a patient receives a biosimilar or originator biological medicine should rest with the clinician 
in consultation with the patient [4]. The BSG however decided to go one-step further, releasing a position 
statement on infliximab brand switching. Their guidance stated that there was sufficient evidence to recommend 
that patients who were in stable clinical response or remission on Remicade® therapy can be switched on the 
same dose and dose interval to biosimilar infliximab CT-P13. This switch should be carried out after discussion 
with individual patients with an accompanying explanation for switching (which is usually on the grounds of 
benefit to the overall service by reduction in costs of the drug and its administration) [19]. Despite the position 
statement from the BSG, this large acute Irish teaching hospital judged that it was premature to switch all of its 
patients from Remicade® to biosimilar infliximab CT-P13.  
                                                                                               Two months later, a review entitled “Switching to 
biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health” 
published in Biologicals journal concluded that whilst prudent switching practices should be employed, growing 
safety experience accumulated thus far with infliximab CT-P13 and other biosimilars was favourable and did 
not raise any specific concerns [21]. Similar evidence that was in favour of switching had also started to surface 
[19,22]. In June 2016, ScienceDaily published a research article on their website entitled “Biosimilar switching 
not suitable for all patients” [23]. At first, it appeared to the consultant gastroenterologist and chief pharmacist 
that this article, based on a study conducted in Spain [24], would counteract previous evidence in favour of 
switching. However, when examined closely, the results of the study showed that when antidrug antibodies 
develop in response to Remicade®, these antibodies also cross-react with biosimilar infliximab CT-P13 as both 
biologics share structural properties, including antigenic epitopes. These findings suggested that antibody-
positive patients being treated with Remicade® should not be switched to biosimilar infliximab CT-P13 since 
these antibodies would also interact with the biosimilar and potentially lead to a loss of response. Despite its 
misleading title, the results of this research article actually emphasised the similarities between the originator 
and biosimilar brands of infliximab and reinforced the science behind the safety of switching. In fact, it should 
be reinforced that antidrug antibodies prevent a switch only if the exposure or clinical effect of the reference 
product is fading.  
                           July 2016 saw the European Commission (EC) release guidance stating that biosimilars, despite 
small differences, were expected to be as safe and effective as the reference medicine [25]. This publication 
followed previous documentation issued by the EC in 2014 explaining the concept of biosimilars to HCPs and 
the pharmaceutical industry [26]. Therefore, based on all the continually emerging evidence in favour of 
switching, the chief pharmacist and consultant gastroenterologist of the large acute Irish teaching hospital 
decided to switch all its patients from originator brand infliximab to biosimilar infliximab CT-P13 commencing 
in September 2016. This decision was relayed to all prescribing physicians during an internal staff meeting 
where the chief pharmacist and consultant gastroenterologist explained the science behind their evidence-based 
decision. All physicians accepted this and agreed to switch patients given the vast amount of evidence 
presented. Physicians agreed to report any ADRs to the HPRA and to the EMA. Hospital budget co-ordinators 
were once again pleased. Although physicians found it more challenging to reassure patients of the switch at 
first, they reported that after informing and addressing all patient concerns at the point of prescribing, no 
opposition to switching arose. 
                                               In October 2016, explorative subgroup analyses of patients with CD and UC in the 
NOR-SWITCH study showed similarity between patients treated with originator infliximab and biosimilar 
infliximab CT-P13 with regard to efficacy, safety and immunogenicity [27]. Although this was one of the more 
large-scale controlled studies where biosimilar infliximab CT-P13 was tested in IBD patients, the small sample 
size of the IBD subgroup was too small to demonstrate any difference in ADR identification or minor 
differences in effect [27]. However, it was still an advancement on previous evidence for switching which was 
more so justified on the concept of extrapolation. The ECCO released an updated statement in December 2016 
that revised its previous guidelines. One of the prominent recommendations was that switching IBD patients 
from the originator brand to a biosimilar product was now deemed acceptable. It also stated that studies of 
switching can provide valuable evidence for safety and efficacy and that scientific and clinical evidence is 
lacking regarding reverse switching, multiple switching, and cross-switching among biosimilars in IBD patients 
[28]. In this rapidly moving field, the evidence is continuing to grow supporting the case that biosimilar 
infliximab CT-P13 is just as safe and effective as the originator biologic. Figure 1 illustrates in diagrammatic 
form, the systematic trail of evidence behind the decision-making process to introduce and switch patients to 
biosimilar infliximab CT-P13 in this large acute Irish teaching hospital. 
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Figure 1 | Independent systematic evidence base behind the decision-making process to implement 
biosimilar infliximab CT-P13 in a large acute Irish teaching hospital for the treatment of IBD 
 
    June 2013                                                         August 2013                                                  September 2014     
 
 
 
 
 
February 2016                                                        July 2015                                                       November 2014                                     
 
 
 
 
 
 
  April 2016                                                               June 2016                                                       September 2016                                                       
 
 
 
 
 
 
 January 2017                                                         December 2016                                                    October 2016 
 
 
 
. 
 
 
 
 
 
 
 
 
Biosimilar 
licenced by 
EMA 
 
 
Use of 
biosimilar in 
new patients  
 
ECCO position 
statement 
not in support 
 
BSG position 
statement 
on infliximab 
switching 
 
Stable 
patients 
switched to 
biosimilar 
 
BSG 
position 
statement 
 
NOR-SWITCH 
data 
ECCO position 
statement in 
support 
 
Biologicals 
paper 
review 
 
Biosimilar 
switching not 
suitable for 
all patients? 
 
NICE: 
Inflectra vs. 
Remsima 
 
Evidence 
continually 
emerging 
 
5 
 
Results and Discussion: 
The decision to treat new and switch existing patients to biosimilar infliximab CT-P13 in this large acute Irish 
teaching hospital was a multifactorial one underpinned by a robust and extensive evidence-based trail that 
ultimately convinced prescribing physicians. From September 2014, all new patients requiring infliximab 
therapy for the treatment of IBD were prescribed biosimilar infliximab CT-P13. In September 2016, all IBD 
patients receiving Remicade® were switched to biosimilar infliximab CT-P13. Switching from originator 
infliximab to biosimilar infliximab CT-P13 in IBD patients occurred in this hospital before any other Irish 
hospital and before the release of the NOR-SWITCH study data. Biosimilar infliximab CT-P13 was first 
licensed in June 2013 [15] but it was not until approximately three years later that prescribers in this large acute 
Irish teaching hospital decided to switch patients. It is evident that there was a significant time lag between 
regulatory approval and clinical acceptance. In fact, Ireland has the second lowest record of biosimilar use due 
to Irish HCPs being slow to accept biosimilars [29,30]. This is possibly owing to a lack of confidence, 
unwillingness or knowledge to prescribe biosimilars which is also seen in other European countries [31]. Work 
which aims to enhance the understanding of biosimilar medicines amongst stakeholders and to encourage best 
practice of biosimilar use is currently being conducted by a collaborative organisation of various interested 
parties [32,33]. However, it could be argued that Ireland has exceptionally low biosimilar uptake because 
biosimilar prescribing is not mandated unlike in other countries [34]. In addition, the Irish biosimilar market 
does not appear very appealing to pharmaceutical companies. Despite the potentially huge cost savings to be 
made from switching, only 54 packets of the biosimilar product Benepali® were sold since its introduction to 
Ireland in August 2016 compared to almost 46,856 of the established originator brand Enbrel® (as of May 
2017) [35]. Furthermore, various funding systems of different countries can too have an impact where, for 
example in the U.K, a major motivation for switching was reinvestment of some of the cost savings in 
improvements to patients’ care [20].  
                                                          The decision by this Irish teaching hospital to switch patients to biosimilar 
infliximab could have been regarded as over cautious, delayed and conservative given that the EMA had already 
licensed the biosimilar medicine three years earlier [15] and thus, one wonders why prescribers had not switched 
patients sooner. With regard to the current biosimilar medicine landscape, it is possible that prescribers may feel 
more comfortable issuing biosimilars if national authorities would actively enforce and implement individual 
EMA biosimilar-related decisions as they are published. The EMA has the best knowledge of biosimilars 
amongst regulators but cannot influence interchangeability that is within the mandate of individual national 
regulatory agencies [10]. These authorities have different capacities to produce information on biosimilars and 
as a result, this situation contributes to the differential rate of acceptance of biosimilars within EU member 
states. With continually emerging positive evidence, it is clear that a three-year time lag for the next biosimilar 
medicine, from market authorisation to the patient switching process, should not occur. Flixabi®, biosimilar 
infliximab SB2 [36], received market authorisation approximately three years after biosimilar inflixmab CT-P13 
[37]. Given its late entry to the market relative to biosimilar infliximab CT-P13, it has been unsuccessful in 
penetrating the Irish market so far. The chief pharmacist and consultant gastroenterologist of this teaching 
hospital note that they would not be comfortable in switching patients from biosimilar infliximab CT-P13 to 
biosimilar infliximab SB2 without conducting a comprehensive review of the available evidence, (especially 
evidence from a switching study), even if the national regulator did declare all licensed biosimilars completely 
interchangeable [11]. Interestingly however, this large acute Irish teaching hospital were content to switch 
patients to Tevagrastim®, a biosimilar of filgrastim [38], from the originator brand without performing such a 
robust evidence review. With regard to the difference between these medicines and their respective disease 
states, the onset of response on neutrophil count from filgrastrim therapy occurs very quickly after 
administration and thus is routinely measured to ascertain treatment effectiveness. In contrast, there is no such 
clear-cut marker for assessing the onset of response from infliximab therapy at these very early stages so this is 
why an extensive evidence review was conducted prior to switching patients. The comparison between the 
implementation of these two biosimilars demonstrates that each biosimilar medicine requires a distinct and 
individualised approach when considering its introduction into the clinical setting; one approach does not suit 
all.  
      In the field of gastroenterology, biosimilar adalimumab, which is licensed to treat IBD, was recently granted 
market authorisation [39]. In the Irish context to date, there has been no major efforts to introduce or switch 
patients to this biosimilar. However, adalimumab is predominantly dispensed by pharmacists in the primary care 
setting. This is in contrast to infliximab, which is commonly dispensed in the secondary care environment. This 
difference is quite interesting as it raises the issue that perhaps primary care pharmacists should be targeted by 
regulatory agencies to encourage patients to switch to biosimilar adalimumab in an effort to increase biosimilar 
medicine market penetration. However, as previously noted, this switch would have to be initiated by the 
prescribing physician [9] and be based upon appropriate evidence. Indeed, there are already many interesting 
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and established approaches to biosimilar medicine implementation which demonstrate that just because a 
biosimilar medicine is licensed, does not mean that its use will be accepted by prescribers nor that all patients 
receiving the originator brand should be automatically switched. One such approach is whereby the American 
National Kidney Foundation sponsored a symposium entitled “Introduction of Biosimilar Therapeutics Into 
Nephrology Practice in the United States” [40]. With anticipated increase in biosimilar products in the field of 
nephrology, mutually accepted lack of knowledge regarding the biosimilar approval process and development, 
and lack of trust with respect to biosimilar medicines’ safety and efficacy, this community of experts decided to 
meet at a nationwide level to discuss the introduction of biosimilars into their area of medicine. The colloquium 
highlighted several controversies but also made recommendations related to public policy, professional and 
patient education, and research needs [40]. With the introduction of new biosimilars set to increase on the 
market in coming years [41], this example of individual fields of medicine taking responsibility for biosimilar 
usage pertaining to their area may be a safe, feasible and effective approach to introduce biosimilars into the 
clinical setting. This strategy might be particularly suitable for fields like oncology and other inflammatory 
diseases where biosimilar usage is set to increase substantially [42,43]. Another possible approach is that 
original biologic and biosimilar medicines can be prescribed on the proviso that patients will be entered into 
disease-specific registries. These registries may be used as surveillance systems for monitoring ADRs, as well as 
to quantify and evaluate the risk-benefit ratio throughout a medicinal product’s life. Registries may be 
particularly effective for the evaluation of rare ADRs occurring in the real world population of treated patients, 
as opposed to the highly selected populations in registration studies [44].   
                                                                                                                     Following on from information 
released by the medicine management programme (MMP) on biosimilars in the Irish healthcare setting in 2016 
[45], and guidance issued by the national cancer control programme (NCCP) on the use of biosimilar medicines 
in oncology in August 2017 [46], the Department of Health (DoH) disseminated a consultation paper in mid-
August 2017 [29]. This paper indicates that the DoH is developing a national biosimilar medicines policy which 
aims to increase biosimilar use in Ireland by creating a robust framework where biologicals and biosimilars can 
be safely, cost-effectively and confidently used in the health service [13]. Table 1 [see electronic supplementary 
material 1 (ESM1)] reveals which topics of interest are being scrutinised. It is hoped this policy will address the 
inter-hospital variation to biosimilar medicine implementation in Ireland and shorten the acceptance process of 
using biosimilars in the clinical setting. An interesting issue raised by the consultation paper is that of 
inappropriate business practices [13]. Although this was not of concern for this large acute Irish teaching 
hospital, impact of the source of information and collaboration of prescribers with the pharmaceutical industry 
can in principle, have an influence on originator product and biosimilar product prescribing patterns. The 
consultation paper highlights that France and Germany have laws banning physicians from receiving gifts from 
pharmaceutical companies. For biosimilar medicine uptake to increase and be maintained, the information and 
evidence used by prescribers must not be tainted with commercial interests. 
                                                                                                                         One of the consultation paper’s 
recurring themes is that there is too much money being spent on originator biologics when there are cheaper, 
equally effective alternatives available. It highlights that only 11 biosimilars are currently reimbursable by the 
Irish healthcare system, while over €200 million is spent each year on biologic drugs that already have approved 
biosimilars or that will have available biosimilars throughout 2018 [13]. It is clear that the potential cost savings 
to be accrued from switching to biosimilars can increase patient access to other new medicinal products. The 
Irish Pharmaceutical Healthcare Association (IPHA) framework agreement plans to save money on biological 
medicines [30,47] where most of these medicines are reimbursed on Ireland’s high-tech medicine scheme. This 
scheme has seen an increase in expenditure from €177.49 million in 2005 to €562.29 million in 2015 [48,49]. 
This prodigious level of pharmaceutical expenditure cannot be maintained. Research from the Irish National 
Centre for Pharmacoeconomics (NCPE) has shown that when pharmaceutical companies submit budget impact 
analyses (BIAs) for new high-cost medicines such as biologics, the majority of these high-cost medicines have a 
greater cost burden on the budget than what is forecasted in their BIAs [50,51]. This results in taxpayers 
spending more than anticipated. Thus, an increase in the uptake of biosimilar medicines would be a more 
sustainable approach to lower the Irish drug bill. One approach the DoH could take would be to establish 
gainsharing agreements at hospital level. Hospitals could be financially awarded for using biosimilars [20] or 
fiscally penalised for lack of utilisation. Gainsharing agreements have already proven to be a powerful incentive 
in increasing biosimilar use at EU level [52]. With respect to the Danish biosimilar landscape, their initial 
passive approach to switching actually led to an administrative order [34]. Thus, another approach the DoH 
could adopt would be to introduce reference pricing of biologic products which would accelerate the path to 
increased biosimilar usage [13]. Reference pricing of SMCE medicines has already resulted in savings of 
millions of euro in the Irish primary care setting [30]. Success of the use of biosimilar infliximab CT-P13 at 
University Hospital Southampton [53,54] and in Norway and Denmark was observed, where biosimilar 
infliximab reached market penetration levels in excess of 90% (as of April 2016) [55]. Such uptake resulted in 
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substantial drug acquisition cost savings and subsequently increased patient access to the biosimilar medicine 
[22,53]. A recent report by QuintilesIMSTM has shown that the entrance of biosimilars into the market increases 
price competition while also generating price reductions for both biosimilar and reference products [56]. 
However, this report stresses that if the problem of low biosimilar uptake is not appropriately managed in the 
long term, this could lead to fewer new biosimilars being developed, reducing overall competitive pressure. 
Conclusion: 
This review examines the evidence used by a large acute Irish teaching hospital to safely and effectively 
introduce biosimilar infliximab CT-P13 into the gastroenterology care pathway. There was a significant time lag 
between regulatory approval and clinical acceptance notwithstanding that the EMA had granted market 
authorisation for biosimilar infliximab CT-P13 three years prior to the initiation of this hospital’s switching 
process. However, the conservative approach to biosimilar infliximab implementation discussed in the review is 
justified given the conflicting and changing evidence disseminated from various sources over this three-year 
period. Alternative approaches that could be used to increase biosimilar medicine adoption into healthcare 
environments have been suggested. Undisputedly, this review demonstrates that increased biosimilar medicine 
usage is of benefit to all stakeholders: increased access for patients, more treatment options for prescribers, 
sustainable healthcare budgets for payers and more business opportunities for manufacturers.  
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